The strong momentum of national biotechs has been partly due to the pandemic, but also to the increased interest of investment funds in them. Innovation of El Mercurio made an analysis of the phenomenon.
According to ACVC data, between 2012 and 2019, about US$20 million was invested in domestic biotech startups. But between 2020 and 2021, investment has risen exponentially with funds raised by NotCo, PhageLab, Protera and Done Properly.
Markus Schreyer, founder and CEO of The Ganesha Lab, says that these experiences and the context of covid have improved the outlook, "by making it more common to talk about biotechnology as an area for the development of technological ventures. We are in a moment of change and maturation like few others, and we have to keep pushing to take advantage of it at a national level".
Francisco Guzmán, president of the ACVC, assures that biotechnology represents a relevant factor for Chile. "This upward curve has been rising for 10 years now, especially in the area of venture capital. It is true that as a result of the pandemic this curve increased exponentially, both in the number of projects and in the increase of investment".
Check out the full article at https://bit.ly/3F4uVny